share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144：拟议出售证券
美股sec公告 ·  05/01 12:54
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 05/01/2024, with an aggregate market value of $386,500. The shares were acquired through stock option exercises on 07/12/2023 and 08/02/2023, amounting to 18,986 and 31,014 shares respectively, both purchased with cash from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 304,591 shares were sold for gross proceeds of approximately $2.98 million. The notice for the upcoming sale was filed on the same day as the planned sale, with the sale instructions having been adopted on 12/27/2023.
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 05/01/2024, with an aggregate market value of $386,500. The shares were acquired through stock option exercises on 07/12/2023 and 08/02/2023, amounting to 18,986 and 31,014 shares respectively, both purchased with cash from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 304,591 shares were sold for gross proceeds of approximately $2.98 million. The notice for the upcoming sale was filed on the same day as the planned sale, with the sale instructions having been adopted on 12/27/2023.
Recursion Pharmicals, Inc.高管兼董事克里斯托弗·吉布森定于2024年1月5日出售5万股A类股票，总市值为386,500美元。这些股票于2023年12月7日和2023年2月8日通过股票期权行使收购，分别为18,986股和31,014股，均以现金从发行人那里购买。此次计划出售是在过去三个月进行的一系列交易之后进行的，共出售了304,591股股票，总收益约为298万美元。即将进行的销售通知是在计划销售的同一天提交的，销售说明已于2023年12月27日通过。
Recursion Pharmicals, Inc.高管兼董事克里斯托弗·吉布森定于2024年1月5日出售5万股A类股票，总市值为386,500美元。这些股票于2023年12月7日和2023年2月8日通过股票期权行使收购，分别为18,986股和31,014股，均以现金从发行人那里购买。此次计划出售是在过去三个月进行的一系列交易之后进行的，共出售了304,591股股票，总收益约为298万美元。即将进行的销售通知是在计划销售的同一天提交的，销售说明已于2023年12月27日通过。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息